Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if they beat this down to 40 cents....i may find a way to get in big time. that's teh equivalent of 2 cents pretty much. small market cap too
that is why i didn't buy pre split.
It needs to be better for most folks are in ULURUVILLE @ .09 or post split has to get to 1.35 for carnage to sell out even.
This stock price has basically been cut in half due to reverse split. IT would've never happened if they stayed on OTC:BB and earned their way back to wallstreet, not trying to disguise or lipstick the pig. Why stay in AMEX? Pride? Well, maybe it shouldn't be in the AMEX...thats what fricken rules are for!!!!!
This kind of business sense is why our nation is in financial quagmires all over our country....................stupid, plain
STUPID
D MODE
I agree that is exactly what happened. I saw an incredible amount of support vanish after folks left at .09. If there were support at that level and then a r/s ULU would be trading at 1.35!!! The support of this stock @ .64 is a joke now. Until this gets over a dollar 35cents, most people are taking a huge tax loss end of 2011
actually, the IR team he hired screwed up. That is why he has chosen an IB related firm to handle the PR from now on. Should do much better.
Dr. Kerry Gray should stay out of the limelight/PR area, he obviosly had no clue how to publicize ULU stock imo. I've always heard doctors make horrible business sense mistakes. It' proves to be here in ULU land the way the PR machine was neglected. All in my opinion.
D MODE
yes a slow grind.........slow.....as in.....they didnt whack it down to 5 out of nowhere right before the split.
it us up to the company to put out good news and instill shareholder trust and ideas of Value.
they stay quiet and this is what happens.
Compared to the volumes of trades at .09 selling pressure subsided after .09 which held some 10,000,000 trades a day periodically. Once that support broke very few shares traded hands. THe R/S could have very easily been @ .09 but someone else had a slow grind down to .0407 in mind. Wonder who so they could get in cheaper prior to the r/s....can you say..
SCAMEX Market Makers???
DUH
D MODE
the point is in regard to your first post. they did not beat it down from .09 right before the split. it was at .05 for a while. so......your post made no sense
Most of the carnage is @ .09 and above....nuff said.
D MODE
where are you getting $.09 though? it was below that for quite some time. they didn't take it to .045 the day before the split.
Ceo's warrants and convertible debt are around .09+ i think.
THey hired a legit team to get this up, and if you read the last Q you will know that sales are expected to pretty much triple in the second half of the year as the new products and marketing (with private placement influx in capital) are administered.
I own ZERO shares at the moment. I think this could be a 100% runner, BUT i know they want some IB financing (hence the split) so we could get hit with a discounted financing at $.55 the second we DO run to $.90 or so.
just my 2 cents.
Reverse split on .09 should be 1.35 post pre split. MMakers dragged this down to .04 and split to .63
Many taking it up the rear here.
D MODE
they have awareness ready. hopefully they split it first. i dont want in yet pre-split
HAH you flat out don't know what YOU are talking about...If the CO. was an individual "person" they'd have chit credit....and the only lender they'll get is a PIPE lender who will "indeed" take a large stake....and they'll dump those shares to get their money back PLUS interest. Its called "death Spiral financing".
...and THAT is exactly what will happen if Kerry doesn't get off his butt. Control over a public Co. that sucks is simply an open check book for the insiders.
ha. you flat out don't know what you are talking about. of course they want a RS. then they can come in and fund the company that has a clean SS and take a large stake in it. they wouldnt want to fund it before the split.
And what would stop the "banking style" fund investors from doing "blind man's" DD and saying "oh...you incompetent losers just did a R/S to pop your PPS"..... "No way Jose'"..."go jump in the lake".....
Hmmm......???
8ks are released after hours. A decision on that split would not be announced during normal hours anywhere. It's completely normal.
the split is necessary to get real funding investment banking style. it's not possible to get large amounts involved when a stock is at 3-15 cents.
Perhaps...but the CEO proved once AGAIN he doesn't give a chit about his shareholders. The Vote / meeting was @ 10:00am
...and he doesn't formally release the 8K / results until AFTER market close. Anyone who was holding or worse...got IN today waiting on the results....gets screwed on market open tomorrow.
CEO allowed everyone to be trapped rather than releasing during market hours ( i.e. = see: "fighting chance" ).
What a sc*mbag
ULU won't have a chance in the long run either until the CEO gets serious about market penetration and hires some REAL talent in the sales and marketing dept. and stops messing around with "shares".
HEAR THAT KERRY !!!??? IT'S CALLED WORKING FOR A LIVING !!!!!
it was always going to pass. it will be good in the long run
REVERSE SPLIT PASSES VOTE!!! bye, bye PPS !!!!
http://biz.yahoo.com/e/110616/ulu8-k.html
if it drops to 2 cents im in
ya. but keeping track of where placements were done at is a good technique imo. ANDS i watch. financed at 1.6-1.8 i think.....so nice discount to that price.
wonder if they are at that conference. ill look
Watching ASCO plays, ASCO is an annual bio conference made some money on pops. Watching DSCO, ABIO but there are many more, tend to be volatile on expectation of info released at the conference.
Wish I had got in OXGN 2 weeks ago, nearly did but grrr backed off.
ULU 10C interesting.
Mainly I am following the hot sector, got my ass burnt being long with these low value stocks, too many issues, RS's , toxic financing, dilution etc, etc.
same. someone felt well enough to put in 500k at ten cents. that is enough to perk my interest when we are at 5 cents. can it go lower? yes. i don't own anything yet because i don't like this recent technical downtrend. maybe in a few weeks i will pick something up. ya i may call them and ask around.
what stocks are you liking?
Sorry have not been following, but I don't think the co is a BK case as mentioned in earlier post, unless something new occured,it's been off my radar.
I just got fed up with stock action, if you find anything out let me know, tia.
thoughts on this one? do we know who made the $500k placement?
well whoever made the private placement for $500k at .10 would feel rather stupid if they went BK a few months later
My guess as soon as they file for chapter 13.
when? if this goes to 2 cents i am in
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001168220%2D11%2D000021%2Etxt&FilePath=%5C2011%5C04%5C05%5C&CoName=ULURU+INC%2E&FormType=PRE+14A&RcvdDate=4%2F5%2F2011&pdf=
Here's the whole thing if people want to read it. Page 34 is where the R/S info starts.
I don't know where this thing is going but it is starting to get interesting. The pps will have to go higher if they are planning on a 1:15 or less R/S and not be delisted.
R/S of 1/15: Procedure for Effecting Reverse Split and Exchange of Stock Certificates
If the proposal to amend the Articles for the Reverse Stock Split is approved by the Company’s stockholders, the Reverse Stock Split would become effective at such time as designated in the Amendment. On the effective date designated in the Amendment, all of the Company’s outstanding common stock will be consolidated at the ratio determined by the Board and set forth in the Amendment, not to exceed 1 for 15.
As soon as practicable after the effective date of the Reverse Stock Split, stockholders will be notified that the Reverse Stock Split has been effected. Continental Stock Transfer & Trust Company, the Company’s transfer agent, will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre-Reverse Stock Split shares will be asked to surrender to the exchange agent certificates representing pre-Reverse Stock Split shares in exchange for certificates representing post-Reverse Stock Split shares in accordance with the procedures to be set forth in a letter of transmittal that will be delivered to the Company’s stockholders. No new certificates will be issued to a stockholder until the stockholder has surrendered to the exchange agent his, her or its outstanding certificate(s) together with the properly completed and executed letter of transmittal.
STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATES AND SHOULD NOT SUBMIT ANY CERTIFICATES UNTIL REQUESTED TO DO SO.
Generally, stockholders whose shares are held by their stockbroker do not need to submit old share certificates for exchange. These shares will automatically reflect the new quantity of shares based on the Reverse Stock Split. If you hold your shares with such a bank, broker or other nominee and if you have questions in this regard, you are encouraged to contact your nominee.
Beginning on the effective date of the Reverse Stock Split, each certificate representing pre-Reverse Stock Split shares will be deemed for all corporate purposes to evidence ownership of post-Reverse Stock Split shares.
Proposal for a R/S in this Form
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61745459
Someone or entity is pissed with this CO or stock, period !
yes,to satisfy the minumum requirements to list on amex
o come on, where do all these giant asks pop out from? This SUX!
I don't know...I saw a rumor on the yahoo board.
.086 already before the open.
Anybody go on the conference call..>?
ULU ~ ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2010
Uluru Inc. Common Stock (AMEX:ULU)
Intraday Stock Chart
Today : Friday 1 April 2011
ULURU Inc. (NYSE AMEX: ULU) today announced its financial results for the fourth quarter and year ended December 31, 2010.
For the fourth quarter of 2010, the Company reported a net loss of $0.3 million, or $0.004 per share, compared with a net loss of $1.7 million, or $0.024 per share, for the same period last year. For the year ended December 31, 2010, the Company reported a net loss of $5.0 million, or $0.06 per share, compared with a net loss of $9.2 million, or $0.14 per share, in the same period of 2009. At December 31, 2010, the Company held cash and cash equivalents of approximately $0.6 million, compared with $1.9 million at December 31, 2009. As of March 1, 2011, the Company held cash and cash equivalents of approximately $0.7 million.
Commenting on the financial results Kerry P. Gray, President and CEO stated, "The 2010 results which reflect a significant improvement in our reported loss from 2009 is due principally to the business restructuring that occurred in July 2009. Non-recurring events accounted for $655,000 of the improvement in 2010 with the balance being attributable to operations. As we expand our commercial activities, both in the U.S. and internationally, we continue to maintain tight controls of our operating expenses. The next 6 months will be an exciting period for the Company as we anticipate three product launches internationally, the submission of two additional 510(k) applications in the U.S. to expand our Altrazeal® product line, significant expansion in Altrazeal® revenues, and additional licensing activities. We are projecting that during this period the Company will receive approximately $2 million from commercial activities."
Operating Results
Revenues
Revenues for the fourth quarter of 2010 were $1,029,000, compared to $233,000 for the fourth quarter of 2009. The increase of approximately $796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due to the recognition of $751,000 in unamortized licensing fees from the termination of the licensing agreement with Meldex International.
For the year ended December 31, 2010, revenues were $1,557,000, compared to $668,000 for the same period of 2009. The increase of approximately $889,000 was due primarily to the following factors: an increase of $903,000 in OraDisc™ licensing fees and an increase of $138,000 in Aphthasol® product sales as we did not sell any Aphthasol® finished product to our domestic distributor during 2009. These increases were partially offset by decreases in Zindaclin® royalty and licensing fees of $87,000 due to our divestiture of this product in June 2010.
Research and Development
Research and development expenses for the fourth quarter of 2010 were $309,000, including $32,000 in share-based compensation, compared to $244,000, including $34,000 in share-based compensation, for the fourth quarter of 2009. The increase of approximately $65,000 in research and development expenses was primarily due to higher costs of $50,000 associated with the development efforts for our Altrazeal® and OraDisc™ technologies.
For the year ended December 2010, research and development expenses were $1.26 million, including $136,000 in share-based compensation, compared to $2.25 million, including $320,000 in share-based compensation, for the same period in 2009. The decrease of approximately $992,000 in research and development expenses was due primarily to decreases in direct research costs of $73,000, scientific personnel costs of $561,000, clinical testing expenses for our wound care technologies of $163,000, and regulatory consulting of $195,000.
Selling, general and administrative
Selling, general and administrative expenses for the fourth quarter of 2010 were $715,000, including $34,000 in share-based compensation, compared to $624,000, including $130,000 in share-based compensation, for the fourth quarter of 2009. The increase of approximately $91,000 in selling, general and administrative expenses was due primarily to additional costs of $30,000 related to the Company's internal sales force, increased director fees of $64,000, higher legal costs of $66,000 and an accounting adjustment of $26,000 that reduced expenses in 2009. These increases were partially offset by a decrease of $96,000 in share-based compensation.
For the year ended December 2010, selling, general and administrative expenses were $3.12 million, including $230,000 in share-based compensation, compared to $5.67 million, including $1.3 million of share-based compensation, for the same period in 2009.
The decrease of approximately $2,546,000 in selling, general and administrative expenses reflects reduced costs associated with our sales and marketing efforts of $1,182,000 due to lower head count and marketing expenses, a decrease of $1,167,000 in administrative compensation including share-based compensation, a decrease of $329,000 in legal fees as 2009 included expenses related to a proposed acquisition, lower consulting fees of $113,000, decreased legal fees related to our patents of $62,000 and lower travel expenses of $38,000.
These expense decreases were partially offset by an increase in director fees of $223,000, increased investor relation expenses of $73,000 and a commission of $30,000 related to the Aiqilin licensing agreement.
Other income and other expenses
For the year ended December 2010, interest and miscellaneous income was $10,000 as compared to $43,000 for the same period of 2009. The decrease of $33,000 is attributable to lower cash balances and interest yields during 2010.
Interest Expense
Interest expense for the fourth quarter of 2010 was $14,000 as compared to $13,000 for the fourth quarter of 2009 and consisted of financing costs for our insurance policies and interest costs related to regulatory fees.
For the year ended December 2010, interest expense was $51,000 as compared to $15,000 for the same period of 2009. The increase of approximately $36,000 is attributable to interest costs related to regulatory fees.
Impairment of Intangible Assets
Yearly, we performed an evaluation of our intangible assets for purposes of determining possible impairment. In 2010 the fair value of our intangible assets exceeded the recorded remaining book value. In 2009 we recognized an impairment charge of $717,000 associated with the valuation of the Zindaclin® patent.
Loss on Sale of Intangible Assets
For the year ended December 2010, loss on sale of intangible assets was $858,000 and consisted of the June 2010 divestiture of our Zindaclin® intangible asset. There was no intangible asset divestiture for the year ended December 2009.
Mr. Gray added, "There were many achievements in 2010 that favorably position the Company for growth in 2011 and beyond including, the granting of the CE Mark, the Distribution Agreement with Novartis, the Altrazeal® Licensing Agreement for China and the significant progress that has been made establishing the base business from which Altrazeal® can favorably compete in the U.S. wound care market. The clinical data that has been developed shows significant pain reduction, the ability to provide a pharmacoeconomic benefit (lower treatment cost and improved clinical outcomes) in the treatment of diabetic foot ulcers, venous leg ulcers and geriatric trauma which are three of the largest segments of the wound care market, and gives us a strong marketing platform. Also, the ability to increase the interval between dressing changes ideally positions Altrazeal® in the large home health care market."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal®, please visit our website at www.altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to future financial performance of ULURU Inc., (the "Company"). The progress of our technology, clinical and regulatory results for our products, advantages of our products, and cost saving initiatives, anticipated product launches and regulatory filings, near term revenue opportunities and anticipated extensions of product lines. When used in this press release, the words "may," "targets," "goal," "could," "should," "would," "believe," "feel," "hope," "expects," "confident," "anticipate," "estimate," "intend," "plan," "potential" and similar expressions may be indicative of forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control. Any forward-looking statement speaks only as of the date on which such statement is made, and the Company undertakes no obligation to update any forward-looking statement or statements to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of an unanticipated event. Further, management cannot assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and other reports filed by us with the Securities and Exchange Commission.
Contact: CompanyKerry P. GrayPresident & CEOTerry K. WallbergVice President & CFO(214) 905-5145
ULURU Inc.
SUMMARY OF RESULTS
STATEMENTS OF OPERATIONS DATA
(Unaudited)
(Audited)
Three Months Ended December 31,
Years Ended December 31,
2010
2009
2010
2009
REVENUES
License fees
$ 949,271
$ 120,735
$ 1,099,554
$ 193,290
Royalty income
25,991
50,908
158,464
255,738
Product sales
53,614
61,249
299,339
180,731
Other
---
---
---
38,190
Total Revenues
1,028,876
232,892
1,557,357
667,949
COSTS AND EXPENSES
Cost of goods sold
10,211
12,290
153,470
35,073
Research and development
309,100
244,083
1,258,060
2,250,153
Selling, general and administrative
714,758
624,242
3,119,881
5,665,559
Amortization of intangible assets
206,454
272,102
905,706
1,065,390
Depreciation
77,020
46,424
256,073
186,690
Total Costs and Expenses
1,317,543
1,199,141
5,693,190
9,202,865
OPERATING (LOSS)
( 288,667)
( 966,249)
(4,135,833)
(8,534,916)
Other Income (Expense)
Interest and miscellaneous income
4,375
274
9,930
42,571
Interest expense
(13,713)
(12,692)
(50,851)
(14,619)
Impairment of intangible assets
---
(716,633)
---
(716,633)
Loss on sale of intangible assets
---
---
(857,839)
---
Loss on sale of equipment
---
---
---
(2,121)
(LOSS) BEFORE INCOME TAXES
( 298,005)
( 1,695,300)
(5,034,593)
(9,225,718)
Income taxes
---
---
---
---
NET (LOSS)
$(298,005)
$(1,695,300)
$ (5,034,593)
$ (9,225,718)
Basic and diluted net (loss) per common share
$ (0.00)
$ (0.02)
$ (0.06)
$ (0.14)
WEIGHTED AVERAGE NUMBER OFCOMMON SHARES OUTSTANDING
82,117,230
71,456,653
81,540,495
67,168,941
ULURU Inc.
SELECTED CONSOLIDATED BALANCE SHEET DATA
December 31, 2010
December 31, 2009
Cash and cash equivalents
$ 641,441
$ 1,934,177
Current assets
1,996,265
3,544,850
Property and equipment, net
1,375,484
1,631,557
Other assets
5,648,764
8,203,965
Total assets
9,020,513
13,380,372
Current liabilities
1,019,597
929,771
Long term liabilities – deferred revenue
594,653
1,272,843
Total liabilities
1,614,250
2,202,614
Total stockholders' equity
7,406,263
11,177,758
SOURCE ULURU Inc.
Yawn is right....your post woke me!
Thought it was going to make a run.....
sdh
ULU started off great this morning but has been extremely boring over the last 2 hrs. yawnnnnnn.
Your probably right, I have not been following it, got bored out of my position a while back, lol.
Yes,,,it should hold until MMakers want it cheaper. They did that a t .09
IMO. The millions of dollars these institutions lost on this POS, now R/S pending just to stay on scamex and Pr's once every 2 months....Uh, If I was big money I'd short this sh*t out of it intraday as well.....Sell High, maybe buy low...just the opposite of most retail....
D MODE
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
801
|
Created
|
05/10/06
|
Type
|
Free
|
Moderators |
ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Hydrogel Nanoparticle Aggregate technology
Contact information:
ULURU Inc.
4452 Beltway Drive
Addison, TX 75001
Tel: (214) 905-5145
Fax: (214) 905 5130
Website : www.uluruinc.com/
Stock Information:
Exchange : AMEX
SEC Filings : sec.gov/cgi-bin/browse-edgar
O/S : 65,582,532 as of March 16, 2009
Transfer Agent :
Continental Stock & Trust Co
17 Battery Place
New York, NY 10004-1123
Tel: 212-845-3212
Fax: 212-616-7616
Product Information:
www.altrazeal.com/
www.uluruinc.com/aphthasol.htm
The Wound, Ostomy and Continence Nurses Society (WOCN), St. Louis, MO, Jun 6-10
New Cardiovascular Horzizons, New Orleans, LA, July 9-12
American College of Foot & Ankle Orthopedics & Medicine (ACFAOM), Orlando, Florida, July 9-12
American Podiatric Medical Association (APMA), Toronto, CAN, July 30 - August 3
Symposium on Advanced Wound Care (SAWC) II, Wash DC, Sep 15-18
Diabet Limb Salvage, Wash DC, Sep 22-25
Clinical Symposium on Advances in Skin & Wound Care (CSASWC), San Antonio, TX, Oct 21-25
VA Podriatic Meeting, Nov
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |